ImmuCell
ICCC
11 hedge funds and large institutions have $1.1M invested in ImmuCell in 2014 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 2 closing their positions.
18% more capital invested
Capital invested by funds: $939K → $1.1M (+$165K)
15% less funds holding
Funds holding: 13 → 11 (-2)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
+$49.3K |
| 2 |
Renaissance Technologies
New York
|
+$5.66K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3.38K |
| 2 |
U
UBS
Zurich,
Switzerland
|
-$3.03K |
| 3 |
TDC
Thompson Davis & Co
Richmond,
Virginia
|
-$3K |
| 4 |
Morgan Stanley
New York
|
-$2.15K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$17 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HP
1
HealthInvest Partners
Stockholm,
Sweden
| $389K | +$49.3K | +11,338 | +16% |
|
|
SRC
2
Shufro Rose & Co
New York
| $248K | – | – | – |
|
|
SKK
3
Shepherd Kaplan Krochuk
Boston,
Massachusetts
| $146K | – | – | – |
|
|
4
Morgan Stanley
New York
| $126K | -$2.15K | -495 | -2% |
|
|
EFS
5
Essex Financial Services
Essex,
Connecticut
| $114K | – | – | – |
|
|
6
Renaissance Technologies
New York
| $66K | +$5.66K | +1,300 | +10% |
|
|
7
Bank of America
Charlotte,
North Carolina
| $9K | -$17 | -4 | -0.2% |
|
|
U
8
UBS
Zurich,
Switzerland
| $5K | -$3.03K | -697 | -41% |
|
9
Creative Planning
Overland Park,
Kansas
| $1K | – | – | – |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| – | -$3.38K | -776 | -99% |
|
|
TDC
11
Thompson Davis & Co
Richmond,
Virginia
| – | -$3K | -750 | Closed |
|
ICCC Hedge Fund Activity: Q1 2014 in Review
11 of the 3,464 institutional investors tracked by Wall St. Rank reported a position in ImmuCell (ICCC) for Q1 2014, worth a combined $1.1M — up 18% from $939K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ICCC and 0 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 2 added.
The largest buyer was HealthInvest Partners, adding an estimated $49.3K. The largest seller was Tower Research Capital (TRC), cutting an estimated $3.38K.
- 11 institutional investors held ImmuCell (ICCC) as of Q1 2014, down from 13 in Q4 2013.
- Funds reported $1.1M of ImmuCell stock for Q1 2014, up 18% quarter-over-quarter.
- 0 funds opened new ImmuCell positions in Q1 2014 and 2 closed out, a net change of -2 holders.
- The largest ImmuCell buyer in Q1 2014 was HealthInvest Partners, an estimated $49.3K added.
- The largest ImmuCell seller in Q1 2014 was Tower Research Capital (TRC), an estimated $3.38K sold.
Based on aggregated 13F filings for Q1 2014.